# Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors

> **NCT02283489** · PHASE2 · UNKNOWN · sponsor: **Renmiao Zhang** · enrollment: 180 (estimated)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** recombinant human endostatin adenovirus
- **DRUG:** Cisplatin injection
- **DRUG:** Paclitaxel injection

## Key facts

- **NCT ID:** NCT02283489
- **Lead sponsor:** Renmiao Zhang
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2014-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02283489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02283489, "Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02283489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*